Incyte Corporation
INCY
|
$52.82
0.19%
0.19%
1.8M
|
Health Technology
(0.0% 1d) (-9.3% 1m) (-28.5% 1y) (0.0% 2d) (0.2% 3d) (-1.1% 7d) (-27.53% volume)
Earnings Calendar: 2024-02-13
Market Cap: $ 11,859,470,081
http://www.incyte.com
Sec Filling | Patents | 1456 employees
(US) Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development and commercialization of proprietary therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late stage development, and commercialized products such as JAKAFI (ruxolitinib), and ICLUSIG (ponatinib). The company was founded by Roy A. Whitfield in April 1991 and is headquartered in Wilmington, DE.
Drugs
JAKAFI (ruxolitinib)PEMAZYRE (pemigatinib)
add to watch list Paper trade email alert is off
Press-releases
CAR T-Cell Therapy for Non-Hodgkin's Lymphoma Market to Showcase Significant Growth at a CAGR of 15% by 2032 | DelveInsight
Published: 2024-04-15 (Crawled : 22:00) - prnewswire.com
INCY | $52.82 0.19% 0.19% 1.8M
|
Health Technology
|
| O: -0.17%
H: 1.41%
C: -0.22%
t-cell for therapy growth market
Incyte to Report First Quarter Financial Results - April 11, 2024
Published: 2024-04-11 (Crawled : 21:00) - biospace.com/
INCY | $52.82 0.19% 0.19% 1.8M
|
Health Technology
|
| O: 0.62%
H: 1.17%
C: -0.76%
first report financial results
CMS and Incyte Announce Collaboration and License Agreement for Povorcitinib in China and Southeast Asia
Published: 2024-04-01 (Crawled : 12:30) - globenewswire.com
INCY | $52.82 0.19% 0.19% 1.8M
|
Health Technology
|
| O: -0.6%
H: 0.0%
C: -0.58%
license collaboration asia agreement china
Incyte and CMS Announce Collaboration and License Agreement for Povorcitinib, an Oral JAK1 Inhibitor, in Mainland China, Hong Kong, Macau, Taiwan and Southeast Asia
Published: 2024-04-01 (Crawled : 17:00) - biospace.com/
INCY | $52.82 0.19% 0.19% 1.8M
|
Health Technology
|
| O: -0.6%
H: 0.0%
C: -0.58%
license collaboration asia agreement
Innovent Dosed First Participant in Phase 3 Clinical Study (Neoshot) of IBI310 (Anti-CTLA-4 Monoclonal Antibody) in Combination with Sintilimab for MSI-H/dMMR Colon Cancer Neoadjuvant Therapy
Published: 2024-03-27 (Crawled : 00:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: -0.26%
H: 0.0%
C: 0.0%
LLY | $745.95 -0.64% -0.81% 1.3M
|
Health Technology
|
| O: 0.49%
H: 0.84%
C: -0.07%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 1.06%
H: 0.0%
C: 0.0%
INCY | $52.82 0.19% 0.19% 1.8M
|
Health Technology
|
| O: -0.09%
H: 1.42%
C: 1.1%
ibi310 first cancer colon therapy study
MorphoSys AG Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
Published: 2024-03-13 (Crawled : 23:00) - biospace.com/
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: -0.23%
H: 0.0%
C: 0.0%
NVS | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: -0.07%
H: 0.09%
C: -0.7%
XNCR | $18.98 -0.47% -0.47% 470K
|
Health Technology
|
| O: -0.66%
H: 4.19%
C: 3.13%
MOR | $18.02 -0.11% -0.11% 590K
|
Health Technology
|
| O: 0.22%
H: 0.22%
C: -0.93%
INCY | $52.82 0.19% 0.19% 1.8M
|
Health Technology
|
| O: 0.03%
H: 1.47%
C: -0.72%
year update financial results
Innovent to Present Preclinical Data of Multiple Novel Molecules at the 2024 AACR Annual Meeting
Published: 2024-03-12 (Crawled : 00:00) - prnewswire.com
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 0.01%
H: 0.0%
C: 0.0%
INCY | $52.82 0.19% 0.19% 1.8M
|
Health Technology
|
| O: -0.12%
H: 0.3%
C: -2.29%
preclinical meeting
Innovent and AnHeart Therapeutics Announce the NMPA of China Has Accepted Second NDA for Taletrectinib for First-Line Treatment of ROS1-Positive Lung Cancer
Published: 2024-03-05 (Crawled : 06:00) - prnewswire.com
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 1.17%
H: 0.0%
C: 0.0%
INCY | $52.82 0.19% 0.19% 1.8M
|
Health Technology
|
| O: 0.4%
H: 0.38%
C: -1.77%
lung cancer treatment therapeutics china
New Data from Incyte’s Growing Dermatology Portfolio to be Presented at the 2024 American Academy of Dermatology (AAD) Annual Meeting
Published: 2024-03-04 (Crawled : 14:30) - biospace.com/
INCY | $52.82 0.19% 0.19% 1.8M
|
Health Technology
|
| O: 0.34%
H: 0.89%
C: 0.79%
meeting growing
Knight Therapeutics Announces Launch of Minjuvi® in Brazil
Published: 2024-02-29 (Crawled : 12:30) - globenewswire.com
XNCR | $18.98 -0.47% -0.47% 470K
|
Health Technology
|
| O: 2.68%
H: 2.22%
C: -1.92%
INCY | $52.82 0.19% 0.19% 1.8M
|
Health Technology
|
| O: 0.38%
H: 0.0%
C: -3.07%
minjuvi brazil therapeutics
Last 15 days Sec forms
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 62% | 38% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $1.45 5.84% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.421 97.65% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.509 23.81% 45.26% 90K
|
GDHG | $0.263 21.76% 40.66% 3.1M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.8 65.02% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
Last 48 Hours Insiders Buying
AXR P 2400 | $22.17 2.69% 0.0% 5.5K
|
Finance
|
21:00
QCRH P 118 | $55.405 1.33% 1.31% 54K
|
Finance
|
18:01
VUZI P 7500 | $1.26 3.28% 3.17% 1M
|
Electronic Technology
|
18:00
RMCF | $3.5501 0.57% 2.22% 18K
|
Consumer Non-Durables
|
20:10